Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy
Erik S. Knudsen, Steven C. Pruitt, Pamela A. Hershberger, et al.
Trends in cancer (2019) Vol. 5, Iss. 5, pp. 308-324
Open Access | Times Cited: 162

Showing 1-25 of 162 citing articles:

Mechanisms driving the immunoregulatory function of cancer cells
Antoinette van Weverwijk, Karin E. de Visser
Nature reviews. Cancer (2023) Vol. 23, Iss. 4, pp. 193-215
Closed Access | Times Cited: 145
CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities
Erik S. Knudsen, Vishnu Kumarasamy, Ram Nambiar, et al.
Cell Reports (2022) Vol. 38, Iss. 9, pp. 110448-110448
Open Access | Times Cited: 86
The role of aberrant DNA methylation in cancer initiation and clinical impacts
Franziska Geissler, Ksenija Nesic, Olga Kondrashova, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 20
The E2F Pathway Score as a Predictive Biomarker of Response to Neoadjuvant Therapy in ER+/HER2− Breast Cancer
Masanori Oshi, Hideo Takahashi, Yoshihisa Tokumaru, et al.
Cells (2020) Vol. 9, Iss. 7, pp. 1643-1643
Open Access | Times Cited: 110
The PI3K/AKT/mTOR and CDK4/6 Pathways in Endocrine Resistant HR+/HER2− Metastatic Breast Cancer: Biological Mechanisms and New Treatments
Daniele Presti, Erica Quaquarini
Cancers (2019) Vol. 11, Iss. 9, pp. 1242-1242
Open Access | Times Cited: 89
Modulation of Phosphoprotein Activity by Phosphorylation Targeting Chimeras (PhosTACs)
Po‐Han Chen, Zhenyi Hu, Elvira An, et al.
ACS Chemical Biology (2021) Vol. 16, Iss. 12, pp. 2808-2815
Open Access | Times Cited: 83
Pan-cancer molecular analysis of the RB tumor suppressor pathway
Erik S. Knudsen, Ram Nambiar, Spencer R. Rosario, et al.
Communications Biology (2020) Vol. 3, Iss. 1
Open Access | Times Cited: 82
Endocrine-Resistant Breast Cancer: Mechanisms and Treatment
Andreas D. Hartkopf, Eva‐Maria Grischke, Sara Y. Brucker
Breast Care (2020) Vol. 15, Iss. 4, pp. 347-354
Open Access | Times Cited: 76
Understanding Lineage Plasticity as a Path to Targeted Therapy Failure in EGFR-Mutant Non-small Cell Lung Cancer
Tatiana Shaurova, Letian Zhang, David W. Goodrich, et al.
Frontiers in Genetics (2020) Vol. 11
Open Access | Times Cited: 71
Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes
Si‐Yang Liu, Hua Bao, Qun Wang, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 62
Rb Tumor Suppressor in Small Cell Lung Cancer: Combined Genomic and IHC Analysis with a Description of a Distinct Rb-Proficient Subset
Christopher A. Febres‐Aldana, Jason C. Chang, Ryan Ptashkin, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 21, pp. 4702-4713
Open Access | Times Cited: 53
Novel insights into RB1 mutation
Yiran Yao, Xiang Gu, Xiaofang Xu, et al.
Cancer Letters (2022) Vol. 547, pp. 215870-215870
Closed Access | Times Cited: 45
Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study
Jingyuan Wang, Joanne Xiu, Alex Farrell, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 2, pp. 151-161
Open Access | Times Cited: 38
Small molecule agents for triple negative breast cancer: Current status and future prospects
Yan Ou, Mengchao Wang, Qian Xu, et al.
Translational Oncology (2024) Vol. 41, pp. 101893-101893
Open Access | Times Cited: 13
A novel lactylation-related gene signature for effectively distinguishing and predicting the prognosis of ovarian cancer
Lei Yu, Chunxia Jing, Sulian Zhuang, et al.
Translational Cancer Research (2024) Vol. 13, Iss. 5, pp. 2497-2508
Open Access | Times Cited: 9
Unraveling the genetic landscape of high-risk retinoblastoma through transcriptome profiling
Mukesh Kumar, Vikas Shrivastava, Isha Goel, et al.
Chemical Physics Impact (2025), pp. 100835-100835
Open Access | Times Cited: 1
Targeting dual signalling pathways in concert with immune checkpoints for the treatment of pancreatic cancer
Erik S. Knudsen, Vishnu Kumarasamy, Sejin Chung, et al.
Gut (2020) Vol. 70, Iss. 1, pp. 127-138
Open Access | Times Cited: 66
Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition
Vishnu Kumarasamy, Paris Vail, Ram Nambiar, et al.
Cancer Research (2020) Vol. 81, Iss. 5, pp. 1347-1360
Open Access | Times Cited: 57
Targeting RB1 Loss in Cancers
Paing Linn, Susumu Kohno, Jindan Sheng, et al.
Cancers (2021) Vol. 13, Iss. 15, pp. 3737-3737
Open Access | Times Cited: 43
Cancer cell cycle dystopia: heterogeneity, plasticity, and therapy
Agnieszka K. Witkiewicz, Vishnu Kumarasamy, Ioannis Sanidas, et al.
Trends in cancer (2022) Vol. 8, Iss. 9, pp. 711-725
Open Access | Times Cited: 30
Evolving strategies and application of proteins and peptide therapeutics in cancer treatment
Anirban Goutam Mukherjee, Uddesh Ramesh Wanjari, Abilash Valsala Gopalakrishnan, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 163, pp. 114832-114832
Open Access | Times Cited: 21
A novel TCGA-validated programmed cell-death-related signature of ovarian cancer
Xintong Cai, Jie Lin, Liu L, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 6
Chemotherapy and CDK4/6 Inhibitors: Unexpected Bedfellows
Patrick J. Roberts, Vishnu Kumarasamy, Agnieszka K. Witkiewicz, et al.
Molecular Cancer Therapeutics (2020) Vol. 19, Iss. 8, pp. 1575-1588
Open Access | Times Cited: 48
Epigenetic silencing of CDKN1A and CDKN2B by SNHG1 promotes the cell cycle, migration and epithelial-mesenchymal transition progression of hepatocellular carcinoma
Bei Li, Ang Li, Zhen You, et al.
Cell Death and Disease (2020) Vol. 11, Iss. 10
Open Access | Times Cited: 45
DDX39B contributes to the proliferation of colorectal cancer through direct binding to CDK6/CCND1
Haonan Zhang, Chengcheng He, Xuxue Guo, et al.
Cell Death Discovery (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 23
Page 1 - Next Page

Scroll to top